



Delivering a healthier future for the UK

Funded by GSK
Job Code: NP-GB-AAP-WCNT-260004
Date of preparation: August 2026

Delivering a healthier future for the UK

Through cutting-edge research, partnerships, and large-scale delivery, GSK is transforming healthcare from treating the symptoms of ill-health, to proactive prevention.

GSK's purpose – drive a prevention-led approach to healthcare that benefits patients, the NHS, society, and our people.



Patients

GSK innovation is putting UK patients back in control of their health.



NHS

GSK supports the NHS's shift from 'sickness to prevention' and aims to reduce illness and enable earlier action to free up frontline NHS capacity.



Society

GSK strengthens the UK's workforce and economy by preventing illness and investing in research and development.




Partnership

GSK forms collaborations because delivering a healthier future for the UK cannot happen in silos.

Patients

GSK innovation is putting UK patients back in control of their health.

Our aim is to positively impact the health of **2.5 billion** people by the end of the decade.¹




More than **> 35 million** packs of GSK medicines and vaccines reach UK patients each year.²

supported by **> £100 million** investment in its UK supply network.³

Patients

GSK has been a leader in the prevention and treatment of respiratory disease for more than five decades, developing medicines and vaccines to help address unmet needs.

Wider access to prevention and long-term condition support and improved disease management helping people stay healthier for longer.



 **~1.5 million** people use GSK respiratory products in the UK.⁴

 **160,000+** COPD patient reviews since 2018.⁵

 **9,000+** patients supported through homecare services.^{6,7}

 **2,300+** patients reached and **432** clinic days delivered through **6** secondary care specialist asthma sites supported across the UK.⁸

Patients

GSK supports the National Immunisation Programme by delivering...

Through ViiV Healthcare we are working to improve the lives of people living with HIV and people who could benefit from HIV prevention.




223,000+

Shingles vaccines since September 2024 - June 2026.⁹



82,000+

Pneumococcal vaccines since September 2024 - June 2026.⁹



NHS

GSK supports the NHS’s shift from ‘sickness to prevention’ and aims to reduce illness and enable earlier action to free up frontline NHS capacity.



NHS

GSK has a strong pipeline of **62 vaccines** and medicines globally and there are **20+** phase III trials expected to start in 2026.¹³

GSK runs **55** clinical trials a year,¹⁴ involving over **1,600** patients.¹⁵



Society

GSK strengthens the UK’s workforce and economy by preventing illness and investing in research and development.

As one of the UK’s largest pharmaceutical employers, with approximately **10,000** employees across **9 sites**,¹⁶ GSK is deeply invested in the country’s long-term success.



Society

To accelerate the supply of new medicines we invested:

> **£1.5 billion** invested annually in UK R&D¹⁷

£400 million

investment to establish new global R&D headquarters in Cambridge.¹⁸

£128 million

to expand manufacturing capacity at Barnard Castle.¹⁹

£82 million

in a state-of-the-art manufacturing facility at our Ware site.²⁰

Partnership

GSK forms collaborations because delivering a healthier future for the UK cannot happen in silos.

Across the UK, we've partnered with the NHS to make care more connected, helping patients through support programs across over **100** hospital trusts and health boards.²¹

GSK ranked

1st

for overall corporate reputation among UK patient groups that work with the company in the 2025/2026 PatientView survey.²²

GSK

References

1. GSK (2025). GSK in the UK Footprint.
2. GSK (2025). GSK in the UK Footprint.
3. Data on file. UK infographic - GSK investment.
4. Data on file. GPrX GP Practice Prescribing Data (2026).
5. Data on file. Interface Clinical Services. 2025.
6. HealthNet (2026). Homecare Report on Respiratory Patients. P1-79.
7. Alcura (2026). ALCURA Patient Registration Reports.
8. Data on File: Severe asthma patient review service. September 2023 to July 2025.
9. Data on file - 2026 internal vaccination data.
10. Data on file: Data Set For Power of Prevention.
11. Data on File - Homecare Impact Calculation.
12. GDS. 2026.
13. GSK Q2 2026 Results Press Release Available at: www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/
14. GSK (2025). GSK in the UK Footprint.
15. GSK (2025). GSK in the UK Footprint.
16. GSK (2025). GSK in the UK Footprint.
17. GSK (2025). GSK in the UK Footprint.
18. GSK Press Release. July 2026. Available at: www.gsk.com/en-gb/media/press-releases/gsk-to-establish-new-flagship-rd-centre-on-cambridge-biomedical-campus-uk/
19. GSK (2025). GSK in the UK Footprint.
20. GSK (2025). GSK in the UK Footprint.
21. Data on file. List of Hospital Trust GSK partners with.
22. Patient View (2026). News Release: The Corporate Reputation of Pharma, 2025/2026 – UK Edition: What 106 UK Patient Groups Say About Pharma. Accessed here: www.patient-view.com/wp-content/uploads/2026/05/2603PAT22May-Corporate-Reputation-of-Pharma-2025-2026-UK-EDITION-FINAL.pdf.

